Qlucore AB (publ) (NOVKAN) - Total Liabilities

Latest as of December 2025: Skr1.67 Million SEK ≈ $179.61K USD

Based on the latest financial reports, Qlucore AB (publ) (NOVKAN) has total liabilities worth Skr1.67 Million SEK (≈ $179.61K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Qlucore AB (publ) cash flow conversion to assess how effectively this company generates cash.

Qlucore AB (publ) - Total Liabilities Trend (2010–2025)

This chart illustrates how Qlucore AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Qlucore AB (publ) to evaluate the company's liquid asset resilience ratio.

Qlucore AB (publ) Competitors by Total Liabilities

The table below lists competitors of Qlucore AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Rajvir Industries Limited
NSE:RAJVIR
India Rs1.13 Billion
Elixxer Ltd
V:ELXR
Canada CA$17.22 Million
LogicMark Inc
NASDAQ:LGMK
USA $2.03 Million
Sadot Group Inc.
NASDAQ:SDOT
USA $57.64 Million
AdCapital AG
F:ADC
Germany €67.13 Million
Dewhurst plc
LSE:DWHA
UK GBX10.81 Million
Eden Research plc
LSE:EDEN
UK GBX2.85 Million
Mitra Komunikasi Nusantara Tbk PT
JK:MKNT
Indonesia Rp462.55 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Qlucore AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Qlucore AB (publ) (NOVKAN) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 10.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qlucore AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qlucore AB (publ) (2010–2025)

The table below shows the annual total liabilities of Qlucore AB (publ) from 2010 to 2025.

Year Total Liabilities Change
2025-12-31 Skr1.67 Million
≈ $179.61K
-63.80%
2024-12-31 Skr4.61 Million
≈ $496.22K
-74.35%
2023-12-31 Skr17.98 Million
≈ $1.93 Million
+30.03%
2022-12-31 Skr13.83 Million
≈ $1.49 Million
+27.19%
2021-12-31 Skr10.87 Million
≈ $1.17 Million
+0.47%
2020-12-31 Skr10.82 Million
≈ $1.16 Million
-59.83%
2019-12-31 Skr26.93 Million
≈ $2.90 Million
+121.21%
2018-12-31 Skr12.18 Million
≈ $1.31 Million
-2.70%
2017-12-31 Skr12.51 Million
≈ $1.35 Million
-7.35%
2016-12-31 Skr13.51 Million
≈ $1.45 Million
+146.21%
2015-12-31 Skr5.49 Million
≈ $590.38K
-39.92%
2014-12-31 Skr9.13 Million
≈ $982.64K
+36.43%
2013-12-31 Skr6.69 Million
≈ $720.27K
-49.18%
2012-12-31 Skr13.17 Million
≈ $1.42 Million
-4.82%
2011-12-31 Skr13.84 Million
≈ $1.49 Million
+370.04%
2010-12-31 Skr2.94 Million
≈ $316.82K
--

About Qlucore AB (publ)

ST:NOVKAN USA Biotechnology
Market Cap
$326.04K
Skr3.03 Million SEK
Market Cap Rank
#30885 Global
#6075 in USA
Share Price
Skr0.03
Change (1 day)
-43.95%
52-Week Range
Skr0.03 - Skr0.23
All Time High
Skr0.23
About

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study… Read more